Health Care • Medical Specialities
$422.02 ▲ +7.61
(+1.84%)
MKT CAP: $91.18B • VOL: 1.04M
52W L $275 52W H $451
ELV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $199.13B | $177.01B | $171.34B |
| YoY Revenue Growth % | +12.5% | +3.3% | — |
| Gross Profit | $177.95B | $157.26B | $75.39B |
| Gross Margin % | 89.4% | 88.8% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $7.20B | $7.86B | $8.50B |
| Operating Margin % | 3.6% | 4.4% | 5.0% |
| Net Income (GAAP) | $5.66B | $5.98B | $5.99B |
| EBITDA (Normalized) | $8.09B | $8.87B | $14.67B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $4.29B | $5.81B | $8.06B |
| Capital Expenditures (CapEx) | $1.12B | $1.26B | $7.71B |
| Free Cash Flow (FCF) | $3.17B | $4.55B | $350.7M |
| FCF Margin % | 1.6% | 2.6% | 0.2% |
| Return on Invested Capital (ROIC %) | 8.7% | 10.0% | 5.4% |
| Cash & Short-Term Equivalents | $9.49B | $8.29B | $22.62B |
| Total Debt (Short + Long Term) | $30.80B | $29.22B | $48.11B |
| Total Stockholders' Equity | $43.88B | $41.31B | $98.69B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ELV.